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Pharmaceutical manufacturers and biotech companies continuously play a significant role 
in the early phases of discovering new drugs. Approximately 6,500 drugs, 40 percent of the 
worldwide total in clinical development, were originated in the U.S. In recent years, there is a trend 
to adopt lean system principles in pharmaceutical industry. This research attempts to study the 
impact of lean system on financial performance of this industry during the last decade. Particularly, 
the researcher performs a qualitative study, followed by the econometric analysis of the efficiency 
ratios and capital structure. The top 10 pharmaceutical companies in the U.S. are selected for this 
research based on various factors. Pearson correlation coefficient and regression analysis are used 
to evaluate the impact of efficiency ratios and capital structure on the financial performance of 
individual companies as well as the overall profitability of the industry. The results from regression 
 
analysis indicate that the capital structure has more influence on profitability instead of efficiency 
ratios in sampled pharmaceutical companies.  
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Chapter 1 : Introduction 
1.1 Background of Pharmaceutical Industry  
The pharmaceutical industry is comprised of companies engaged in researching, 
developing, manufacturing and distributing drugs for human or veterinary use. A recent report 
published by Statistic Inc. reveals that the U.S. pharmaceutical industry valued around $446 billion 
dollars in 2016. Based on the revenue of global pharmaceutical market, six of the top 10 companies 
were from the United States. The top pharmaceutical companies made a big contribution to the 
U.S. economy along with a large expenditure on biopharmaceutical research and development. 
The annual cost of developing new drugs is approximately 60 billion dollars (Pharmaceutical 
Industry in the U.S., n.d.).   
The pharmaceutical industry makes great contribution to society by producing medications 
that prevent infections, maintain health and cure diseases. The process for launching a new drug 
with patent protection is time consuming. Getting the drug approval from the U.S. Food and Drug 
Administration takes four to eight years and the patents only lasts approximately 20 years (Finkel, 
2012). With the recent implementation of the Affordable Care Act (ACA), more pharmaceutical 
companies are facing drastic changes in recent years as a result of decreasing profit margins, 
growing scrutiny from the public, increasing pressure from regulatory agencies and rising 
uncertainty from an ever-changing political landscape (Peters, 2013). Additionally, a lot of patents 
are expiring, resulting in a reduced brand spending of US $127 billion through 2016 (The Global 
Use of Medicines:Outlook Through 2016, 2012).  
The pharmaceutical companies have to use their assets in an effective way and pursue cost 
reduction through various management approaches, such as lean manufacutring. Lean 
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manufacturing was originally created by Toyota to eliminate waste and inefficiency in its 
manufacturing operations. Lean can be applied to any business or production process in any 
industry. Historically, global pharmaceutical companies have implemented lean systems to 
improve productivity and inventory management (Crawford, 2016). 
1.2 Statement of the Problem 
In response to changing competitive landscape in pharmaceutical industry, many 
companies have chosen to implement lean management approach to create more value for 
customers with less resources and wastes (“Improvement of Manufacturing Operations”, 2014). 
Since the goal of lean practices is to reduce the operating costs, there is a need to investigate the 
effectiveness of applying lean principles in the pharmaceutical industry. This research focuses on 
studying the impacts of lean practices on U.S. pharmaceutical industry by using historical 
efficiency ratios, capital structure, and profitability metrics. The relationship between these metrics 
is analyzed by Pearson correlation and single regression analysis models. Thus, the findings of this 
study provide insights into the changes that have affected the US pharmaceutical industry and help 
researchers develop better understanding of the historical and current financial performance and 
future investment plans of individual companies in this sector.  
1.3 Significance of the Study 
In a long-term cross-industry study that uses inventory turns as an indicator, 
pharmaceutical companies hold the bottom spot. This research analyzes the effects of lean 
practices on the working capital management of companies within the US pharmaceutical industry. 
The econometric analysis presented in this research provides better understanding of historical 
trends and the relationship between efficiency ratios and the profitability of individual companies 
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and the pharma sector as a whole.   
1.4 Research Objectives 
This study has three main objectives: 
 Provide an overview of U.S. pharmaceutical industry and study the implementation of lean 
practices in pharmaceutical manufacturing. 
 Study and analyze historical trends in efficiency, capital structure, and profitability ratios 
in the U.S. pharmaceutical industry. 
 Factor analysis of historical efficiency and capital structure ratios and their impact on the 
profitability of the U.S. pharmaceutical industry. 
1.5 Definitions of Terms 
The following content defines important terms used in the study. Those terms and the 
abbreviations are mainly used in ratio analysis, which is a quantitative analysis of information 
contained in a company’s financial statements (Drake, n.d.). In the data analysis and research 
methodology, the terms are replaced by the abbreviations.   
Return on Assets (ROA) is a financial ratio that shows the efficiency of a firm in using its 
assets to generate earnings. It is calculated as the net income divided by the total assets. The assets 
are read from the balance sheet and include cash and cash-equivalent items, such as receivables, 
inventories, land, capital equipment as depreciated, and the value of intellectual property such as 
patents. 
 Return on Invested Capital (ROIC) is calculated by taking the after-tax operating profit 
of the business and dividing it by invested capital. For mature companies, maximizing ROIC 
should be one of the key goals. More profit with lower capital means more money that the business 
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can return to shareholders. 
Days Sales Outstanding (DSO) is a calculation used by a company to estimate its average 
collection period. It is a financial ratio that illustrates how well a company's accounts receivables 
are being managed.  
Days Inventory Outstanding (DIO) indicates how many days on average a company turns 
its inventory into sales. It is also defined as days in inventory (DII). Value of DIO varies from an 
industry or company to another. In general, a lower DIO is better. 
 Days Payable Outstanding (DPO) is an efficiency ratio that measures the average number 
of days a company takes to pay its suppliers. DPO provides one measure of how long a business 
holds onto its cash. Having a greater days payables outstanding may indicate the company's ability 
to delay payment and conserve cash.  
Cash Conversion Cycle (CCC) is a process or a cycle where the company purchases 
inventory, sells the inventory on credit as an account receivable, and then collects the account 
receivable or turns it into cash. CCC measures the time devoted in converting inventory and 
receivables to cash, as well as the amount of time the company is given to pay its bills without 
incurring any penalties.  
Inventory Turnover (IT) is a ratio showing how many times a company's inventory is 
sold and replaced over a period of time. The days in the period can then be divided by the inventory 
turnover formula to calculate the days it takes to sell the inventory on hand. It is calculated as sales 





Chapter 2 : Literature Review 
This chapter presents a review of previous studies relating to the research topic selected for 
the present study and enables the researcher to gain in-depth knowledge over the various concepts 
of financial ratios and Lean Systems. It is organized in four sections. First, an overview of the 
pharmaceutical industry (global as well as US) is provided. Next, the literature review focuses on 
Lean Systems and their applications in Pharmaceutical manufacturing. Last, the efficiency ratios 
and profitability metrics used in this research are discussed. 
2.1 Overview of Pharmaceutical Industry 
The world prescription drug market grew a little more in 2017 than in 2016. This was due 
to the depreciation of the USD against other foreign currencies, especially the Japanese yen. 
Meanwhile, big drug makers were struggling with governments’ tightening of cost controls and 
growing criticism about the soaring prices of new medicines (GLOBAL PHARMACEUTICALS 
REPORT, n.d.). Although the weak economic growth and increasing pressure on drug prices 
continued in 2017. A worldwide pharma review showed that prescription drug sales were 
forecasted to grow at an impressive annual compound rate of 6.5%, eventually hitting $1.06 trillion 
worldwide in 2022 (EvaluatePharma, 2017). Figure 2.1 below shows the worldwide total 




Figure 2.1 Worldwide Total Prescription Drug Sales (2008-2022) Data: EvaluatePharma (2017) 
2.1.1 Pharmaceutical market in the world 
The US has the largest pharmaceutical market in the world with a value of $339,694 million 
USD followed by Japan ($94,025 million USD) and China ($86,774 million USD). In Germany, 
the value of its pharmaceutical market is about $45,828 million USD and, in France, it is about 
$37,156 million USD. In Brazil, the value of its pharmaceutical market is about $30,670 million 
USD. In Italy, the value is about $27,930 million USD. In the UK, it is about $24,513 million USD 
while in Canada it is about $21,353 million USD. In Spain, it is about $20,741 million USD 
(Biggest Pharmaceutical Markets In The World By Country, n.d.). 
2.1.2 Value of the U.S. pharmaceutical industry 
The U.S. pharmaceutical industry is one of the most critical and competitive sectors of the 
economy. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), 
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more than 810,000 people work in the biopharmaceutical industry in the United States across a 
broad range of occupations, such as scientific research, technical support and manufacturing. 
Directly and indirectly, the industry supports over 3.4 million jobs across the United States and 
added an estimated $790 billion to the economy in 2014. Although manufacturing jobs supported 
by the industry are expected to decline over the next decade due to continued productivity gains, 
it will remain an important source of high-pay jobs, providing salaries way above the national 
average (International Trade Administration, 2016). 
2.2 Lean System 
The roots of Lean can be found in the Japanese company, Toyota. The origins of Toyota 
Production System date back to the beginning of the twentieth century. The inventor of the system 
was Sakichi Toyoda who invented a motor-driven loom with a specialized mechanism devised to 
stop in case of breaking off the thread. The mechanism became a foundation for Jidoka (automation 
with human manufacturing). Kiichiro Toyoda, the founder of Toyota Motor Corporation, directed 
the engine casting work and discovered many problems in their manufacturing process. In 1936, 
his processes hit new problems and he developed the “Kaizen” improvement teams. Toyota’s view 
is that the main method of lean is not the tools, but the reduction of three types of waste: 
1 muda (“non-value-adding work”) 
2 muri (“overburden”) 
3 mura (“unevenness”) 
Taiichi Ohno advanced another concept called “pull-flow production”, an old practice in 
American supermarkets. The pull-flow production allowed to generating as many products as it 
could be exploited in the successive process. In turn, it would facilitate the reduction of 
overproduction (Dekier, 2012). 
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2.3 Applications of Lean System in general Industry 
Lean management is an approach to running an organization that supports the concept of 
continuous improvement. It is an ongoing effort to improve products, services, or processes, which 
require “incremental” improvement over time in order to increase efficiency and quality. 
Many industries are making an effort to integrate Lean into their existing process-
improvement framework. Lean is a continuously developing philosophy and its application is 
different for each company. Most companies can merge Lean into a mature Six Sigma framework. 
An evaluation of the various principles of Lean has been conducted within a business unit of a 
Fortune 10 company to determine which could be subtly introduced and used effectively to 
augment the existing Six Sigma framework. They found that the following five Lean tools and 
principles were particularly applicable (Roy, n.d.).  
2.3.1 Value Stream Mapping 
In the Analyze phase of a DMAIC project, a value stream map can be created that shows 
the flow of materials and information, and categorizes activities into three segments: value 
enabling, value adding and non-value adding. The focus of this tool is on identifying and 
eliminating the non-value added activities in each process step and reducing the wait time between 
consecutive steps wherever possible. Value enabling activities, are activities that do not directly 
add value to a customer, but must be performed to allow value adding activities later on, however, 
cannot be totally eliminated from a system. Instead, they can be sub-classified into value adding 
and non-value adding activities, eliminating non-valued added activities. These eliminations help 
make a process more compact – a benefit in process improvement projects aimed at reducing 




2.3.2 Takt Time 
Takt is a German word that can be roughly translated as “beat.” Takt time is the rate at 
which a completed project needs to be finished in order to meet customer demand. For processes 
involving cycle times, such as manufacturing or incident management, the as-is cycle time can be 
captured in the Measure phase. Then, during the Analyze phase, the cycle time can be compared 
with existing service level agreements (SLAs). If a mismatch exceeds the tolerance, improvements 
would be needed to match the cycle time with the takt time for the system. 
2.3.3 Ishikawa (Cause-and-Effect) Diagram and 5 Whys 
In the Analyze phase, the absence of concrete statistical data sometimes can make the 
identification of a root cause difficult. In those scenarios, the 5 Whys – asking “Why?” five times 
– along with a cause-and-effect diagram, can make the task more manageable. The 5 Why’s tool 
also can help uncover the process dynamics and the areas that can be addressed easily. 
2.3.4 Heijunka (Load Balancing) 
A Japanese term, Heijunka refers to a system of production designed to provide a more 
even and consistent flow of work. This principle can be incorporated in the Design phase if the 
root cause analysis during Analyze points to bottlenecks in the process. Load balancing can be 
used to introduce a pull in the system rather than letting it operate on push, thus alleviating the 
bottlenecks. Efforts for introducing a level load balance in the system also automatically reduce 




2.3.5 Poka-yoke (Mistake Proofing) 
A Japanese phrase meaning mistake proofing, poka yoke can be used with DMADV 
(Define, Measure, Analyze, Design, Verify) to tune process steps. A combination of an Ishikawa 
chart and Pareto analysis can be useful in “Analyze” in listing the major issues plaguing the as-is 
process. During the Improve and Design phases, the possibilities for eliminating a major cause of 
errors can be explored by improving or redesigning the system to avoid error-inducing scenarios. 
2.4 Study of Lean System in Pharmaceutical Industry 
A recent research presented a successful case study of a pharmaceutical company with a 
focus on efficiency improvement in lean system (Nenni M., Giustiniano L., Pirolo L., 2014). It 
demonstrated the positive effect of lean system on increasing efficiency. The pharmaceutical 
industry was a well-known example of a crisis-affected context and companies directed attention 
to Lean Management for a long time, but they were stable in increasing effectiveness. The research 
used a case study to move the attention to efficiency as an attractive LM goal. 
Another research shared improvement experiences due to implementation of lean 
principles combined with the current good manufacturing practices (cGMP) in a pharmaceutical 
company (Chowdary & George, 2011). The methodology applied in the company contributed in 
reducing lead times, cycle times and Work in process (WIP) inventory in the manufacturing 
process. Furthermore, the storage area was reduced by 38 per cent and production staff was 
reduced by 50 per cent. 
Rafi Maslaton (2012) discussed that the key challenges in adopting lean manufacturing. 
He was following the origins of the concept and choosing the effective approaches and tools to 
better fit to their business goals. The research focused on several key lean tools and provided 
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guidance of which tool would add value and which tool was not designed for pharmaceutical 
industry. He introduced tools and approaches such as Single Piece Flow, 5S, OEE, Value Stream 
Mapping, KANBAN, JIT. 
Boltić, z. et al. (2016) evaluated the relationship between quality assurance and 
implementation of cleaner production in the generic pharmaceutical industry through the 
comprehensive concept of continuous improvement. It was mostly related to the application of 
Lean Six Sigma and other known concepts used in the industrial environment. Two representative 
case studies were selected for comparative analysis, also considering relevant regulatory 
requirements in the field of quality management, as well as appropriate quality standards. They 
developed an engineering approach to evaluation of the production systems in terms of continuous 
improvement concepts application, considering both quality aspects and efficiency of such 
systems. 
2.5 Summary 
Based on the previous literature reviews, there are limited quantitative researches to 
analyze the effectiveness of lean system in pharma industry. The aim of this paper is to find some 
key factors to evaluate the impact of Lean approach in the U.S. pharmaceutical industry and 
interpret the historical trend of the pharma companies’ financial performances by efficiency ratios, 
capital structure ratios and profitable metrics.  
12 
 
Chapter 3 : Methodology 
3.1 Research Design 
The data required for this research have been extracted from the annual reports of a selected 
group of U.S. pharmaceutical companies. The research methodology includes a variety of 
quantitative methods with financial ratios and regression analysis tools. 10 companies are selected 
with consistent financial data covered a period of ten years starting from 2008 to 2017. 
3.2 Sample 
Initially a sample of 12 companies is considered and the companies those do not have a 
consistent track record for ten years or more are eliminated from the list. Finally the financial data 
of 10 companies are obtained. The sample selected from top 10 pharmaceutical companies based 
on their revenue in 2016. The following is the summary of each company.   
3.3 Review of the 10 Pharmaceutical Companies 
3.3.1 Pfizer Inc. 
Pfizer is founded in 1849 by Charles Pfizer and Charles F. Erhart. It is considered one of 
the world's largest pharmaceutical companies. In 2018, Pfizer saves a tax of $10.7 billion over the 
next eight years on its overseas earnings. However, the Pfizer Chief Executive Ian Read described 
the tax changes as positive that drops effective tax rate 6 to 17 percentages. As a result of savings 
from the tax changes, Pfizer made a $200 million contribution to the company’s charitable 
foundation, a $100 million in bonuses to employees and a $500 million contribution to its U.S. 
pension plan by the end of September. The expected revenue in 2018 is $55.5 billion as growth in 
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key products like breast-cancer drug Ibrance, bloodthinner Eliquis and arthritis treatment Xeljanz 
(Rockoff & Moise, 2018). 
Pfizer’s quality control (QC) laboratory in Puurs, Belgium, has been applying lean 
techniques to reduce the total throughput lead time for products across the entire supply chain for 
several years. In 2009, the lab set its sight on reducing lead times by 25% for eight major products. 
In 2010, having met that target, it looked to the next level of quality improvement, the Pfizer lean 
laboratory initiative (DeWit, 2011). 
3.3.2 Merck & Company, Inc. 
Merck & Company, Inc. is one of the largest pharmaceutical companies in the world. It 
was established in 1891 in the United States while its parent company was founded in Germany in 
1668 by the Merck family. The company sells a vast array of products, including Thiazide anti-
hypertensives, First statin, vaccines, antibiotics, blood pressure drugs, heart drugs and Vioxx. 
Vioxx, a painkiller was associated with 20,000 hospitalizations and 2000 deaths each year (″Merck 
& Co. Settles Vioxx″, 2016). 
Merck Manufacturing Division set a goal to have a total lead time of 90 days from 
formulation to the patient, which is about one-quarter of the current time in 2016. Dr. Christine 
Moore discussed the plan to accomplish the goal with an example product that was easy to 
manufacture and had a very well-controlled process. The company is working on their pursuit of 
worldwide approval of continuous manufacturing for solid oral dosage products (Gladd, 2016). 
3.3.3 Johnson & Johnson 
Johnson & Johnson (J&J) was established by 1886. It is an American multinational medical 
devices, pharmaceutical and consumer packaged goods manufacturing company.  The corporation 
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includes some 250 subsidiary companies with operations in 60 countries and products sold in over 
175 countries. Johnson & Johnson had worldwide sales of $70.1 billion during calendar year 2015. 
The same year, one small lean team at the Customer & Logistics Services-North America 
(CLS-NA) group decided to develop a network of professionals focused on continuous 
improvement within Johnson & Johnson and their supply chains. The team faced some barriers at 
the beginning until the lean leader initiated a small project to show the successful result by lean 
approach which achieved more than $1.8 million in cost savings (Rennie, 2017).    
3.3.4 Gilead Sciences, Inc. 
Gilead Sciences, Inc. is a research-based biopharmaceutical company concentrated 
primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, 
including Harvoni and Sovaldi. It was founded in 1987.  The company has recently acquired Kite 
Pharma, a specialty cancer immunotherapy drug developer. As Kite grew sales nearly 100% 
annually and reached $35 million in revenues for 2017, it has been integrated into Gilead's 
inorganic R&D facilities and will begin generating revenues for the company (“2018 Is Gilead's 
Year”, 2018).   
 In 2015, Gilead Sciences was selected in a list based on the contributions in innovation to 
the world. 50 companies were on the list and Gilead Sciences was ranked as 8 but also the first 
one as a pharmaceutical firm. The company was chosen by the scientific expertise combined with 
lean R&D (Ringel, 2015). 
3.3.5 Amgen Inc.  
Amgen Inc. is a multinational biopharmaceutical company founded in 1980. It is also 
known as Applied Molecular Genetics before the name changed. The former name shows that they 
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have concentrated on the research of molecular genetics to unravel the roots of disease.  It has a 
presence in approximately 100 countries and regions worldwide by 2017. The company’s 
innovative medicines are focused on six therapeutic areas: cardiovascular disease, oncology, bone 
health, neuroscience, nephrology and inflammation (“Quick facts”, n.d.). 
In 2008, one researcher at MIT suggested Amgen to adopt lean practice in their operations. 
A continuous improvement methodology and strategies were constructed along with the creation 
of a training curriculum and the initial implementation of the continuous improvement 
methodology at specific manufacturing sites (Villa, 2008).  
3.3.6 Allergan, Plc. 
Allergan, Plc was established for the purpose of facilitating the business combination 
between Actavis, Inc. and Warner Chilcott plc (“Warner Chilcott”). It is a global pharmaceutical 
company. The company is focused on developing, manufacturing and commercializing branded 
pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around 
the world. The recent report shows that the company faces patent losses for Restasis, Combigan 
and Estrace. Those medications represent a combined 15% of total revenue (Bryson, 2018). 
According to the Allergan Sustainability Performance Report in 2011, the company had 
set an aggressive goal to reduce the water consumption by 15% in 2015 by using lean 6 sigma 
processes. 
3.3.7 Bristol-Myers Squibb. 
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic 
areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid 
arthritis and psychiatric disorders. The headquarter is located in New York City. It was first 
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founded in 1858 by Edward Robinson Squibb in Brooklyn. In 2017, the company’s fourth quarter 
revenue increased 4 percent to $ 5.4 billion, the full year revenue increased 7 percent to $20.8 
billion (“Bristol-Myers Squibb Reports”, 2017). 
One of Bristol-Myers Squibb's manufacturing facilities applied lean methodologies, 
deploying lean software and focusing on team-building produced dramatic results. Cycle times 
were slashed by 80 percent, work-in-progress (WIP) was reduced by 75 percent, inventory turns 
increased fivefold, employee productivity doubled (output per employee hour) since the 1990s, 
and first-pass quality rose to 95 percent in the last three years despite a significant increase in 
product variability (Noria Corporation, 2006). 
3.3.8 Eli Lilly and Company 
Eli Lilly and Company is a global pharmaceutical company founded in 1876 by Col. Eli 
Lilly. It is the first company that implements mass production of penicillin, polio vaccine and 
insulin. Eli Lilly and Co. is currently the largest manufacturer of psychiatric medications and 
produces Prozac (fluoxetine), Dolophine (methadone), Cymbalta (duloxetine), and Zyprexa 
(olanzapine). It is ranked 132nd on the Fortune 500. The 2016 financial report indicates that the 
company increased 6 percent of total revenue to $ 21.2 billion. 
A researcher built a lean lab system for the company in 2011 by Lean Six Sigma to transfer 
the data into electronic based instead of paper based. The implementation of the lean program 
reduced 50% of the cycle time for documentation. This lean program also brought benefits in 
reduction of production time, cost savings (Longden, 2011). 
3.3.9 Abbott Laboratories 
Abbott Laboratories is a multinational company that engages in the discovery, 
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development, manufacture and sale of a broad and diversified line of health care products. The 
revenue generated in 2017 is $27.4 billion. Its pharmaceuticals include HIV treatments Norvir and 
Kaletra, rheumatoid arthritis therapy Humira, and Lupron to treat endometriosis and prostate 
cancer. Its well-known brands in nutritional products division include Similac infant formula and 
the Ensure line of nutrition supplements. The company also makes diagnostic instruments 
(including tests and assays), vascular medical devices such as its Xience drug-eluting stents, and 
the FreeStyle diabetes care line, as well as products for the eye.  
In 2013, Abbott Laboratories cooperated with Association of public health laboratory 
(APHL) to initiate a pilot project of Lean workflow assessments in three member laboratories.  
3.3.10 Biogen, Inc. 
Biogen, Inc. (previously known as Biogen Idec) is an American multinational 
biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, 
development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and 
autoimmune diseases to patients worldwide. 
A senior quality manager conducted a case study on implementing lean approach for 
validation of life cycle management that resulted in productivity improvements greater than 100%, 
cycle Time improvements greater than 50%, and equipment change over resource cycle time 
efficiency improvements of 85% (Tessneer, 2017). 
3.4 Factors used for analyzing the impact of lean practices 
Although there is no universally accepted measure of a company’s “Leanness”, Days 
inventory turnovers are a reliable indicator (Robert, 2009). The trend of inventory turnover is 
calculated from the cost of goods sold divided by the average inventory. It indicates how well a 
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company is progressing in terms of becoming more lean and improving its processes. 
3.5 Data Collection and Ratios Calculations 
A quantitative study for studying historical trends in efficiency, capital structure and 
profitability ratios in the U.S. pharmaceutical industry follows by the qualitative study. The data 
are collected from companies’ income statements and balance sheets and subsequently efficiency 
ratios, capital structure ratios, and profitability ratios are calculated for the 10-year period for each 
company. These calculations are explained in the sections below. 
3.5.1 Efficiency ratios 
In general, efficiency is the ability to achieve the required accomplishment with a minimum 
amount or quantity of waste, expense, or unnecessary effort. In the mathematical or scientific 
terms, it is a measure of the extent to which input is well used for an intended task (output). 
Efficiency is a measurable concept, quantitatively determined by the ratio of useful output to total 
input. Efficiency ratios are a series econometric tools used to measure how effectively a company 
manages its assets and liabilities to maximize profits. It can be applied for any industries (Hossan 
and Habib, 2010). 
3.5.2 Calculation of Efficiency ratios 
Days Sales Outstanding (DSO) is a calculation used by a company to estimate its average 
collection period. It is a financial ratio that illustrates how well a company's accounts receivables 
are being managed.  
The days sales outstanding is calculated as: 
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Days of Sales Outstanding = 
Accounts receivables
Sales / 365
  (3.1) 
Table 3.1 shows the calculated DSO for the 10 sampled firms during 2008 - 2017. The 
abbreviations are the short terms (ticker symbols) for the companies, which can be found in 
Appendix A.  Data used in calculation were extracted from each company’s annual report.  
Table 3.1 Days of Sales Outstanding (DSO) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 71.04 56.74 54.86 62.20 50.77 41.18 70.44 48.83 64.36 37.38 
2009 86.14 69.08 57.10 62.81 52.13 53.88 66.70 51.17 71.23 41.60 
2010 78.74 55.35 57.54 69.14 53.88 55.28 62.23 54.07 71.23 44.75 
2011 76.38 59.27 57.12 77.77 61.27 68.73 49.22 53.29 69.84 43.01 
2012 80.40 61.52 59.43 69.64 57.23 76.18 55.23 55.99 70.01 42.06 
2013 76.90 61.57 58.92 62.75 50.96 56.96 53.16 53.46 96.89 39.79 
2014 66.32 59.67 55.73 49.38 47.69 52.77 43.56 62.05 68.25 39.81 
2015 62.93 60.57 56.56 58.65 46.68 57.81 55.63 61.70 62.64 42.72 
2016 56.66 61.90 56.95 62.26 48.90 61.78 63.15 64.86 58.34 42.54 
2017 57.12 63.19 60.13 58.48 51.13 62.17 71.34 68.43 56.62 48.01 
 
Days Inventory Outstanding (DIO) indicates how many days on average a company turns 
its inventory into sales. It is also defined as days in inventory (DII). Value of DIO varies from an 
industry or company to another. In general, a lower DIO is better. 
The days inventory outstanding is calculated as: 
Days Inventory Outstanding = 
Inventories
Cost of goods sold / 365 
 (3.2) 
Table 3.2 shows the calculated DIO for the 10 sampled firms during 2008 - 2017.  
Table 3.2 Days Inventory Outstanding (DIO) for the sample of 10 firms during the last decade. 
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Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 217.84 136.14 100.19 247.35 331.14 117.03 112.05 208.90 82.88 225.90 
2009 344.63 209.20 101.23 226.43 374.86 133.20 112.84 229.60 83.46 266.30 
2010 233.27 138.12 102.53 220.14 348.72 120.84 90.51 224.36 80.31 265.83 
2011 195.67 131.13 104.54 222.82 338.83 108.18 84.37 173.48 76.02 240.81 
2012 238.82 141.92 116.12 231.50 326.97 130.94 120.39 188.10 85.42 259.02 
2013 251.86 137.36 125.57 242.66 314.33 129.54 124.66 207.21 117.89 235.41 
2014 225.41 128.40 128.87 165.82 233.84 111.80 141.93 209.74 105.64 228.00 
2015 249.24 125.52 137.60 152.20 219.41 117.05 129.84 224.11 109.37 249.74 
2016 211.60 125.68 136.31 151.71 227.14 169.45 102.69 226.16 101.79 233.88 
2017 233.17 142.31 121.71 99.70 250.23 136.58 82.07 241.13 89.28 213.21 
 
Days Payable Outstanding (DPO) is an efficiency ratio that measures the average number 
of days a company takes to pay its suppliers. DPO provides one measure of how long a business 
holds onto its cash. Having a greater days payables outstanding may indicate the Company's ability 
to delay payment and conserve cash. 
The days payable outstanding is calculated as: 
Days of Payables Outstanding = 
Accounts payables
Cost of goods sold / 365 
  (3.3) 
Table 3.3 shows the calculated DPO for the 10 sampled firms during 2008 - 2017.  
Table 3.3 Days Payable Outstanding (DPO) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 90.46 40.61 142.09 144.34 70.11 65.53 84.94 79.30 37.20 89.93 
2009 125.68 57.76 129.04 161.48 94.09 113.89 115.25 79.66 36.36 107.92 
2010 94.13 45.09 108.42 157.48 106.05 75.83 127.75 85.28 35.05 128.15 
2011 95.12 51.60 101.72 172.59 102.12 69.10 149.51 79.13 38.25 136.44 
2012 130.43 46.77 97.38 187.08 96.75 72.91 190.22 88.03 42.46 130.63 
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2013 142.75 43.35 98.81 164.93 92.29 23.29 188.11 85.80 51.31 90.20 
2014 127.18 53.32 111.52 106.52 82.50 18.66 234.21 83.15 41.38 69.99 
2015 133.55 63.03 121.19 97.17 93.99 38.47 189.18 89.36 44.75 73.06 
2016 120.73 70.16 114.34 102.11 82.52 58.29 119.15 86.73 45.69 67.53 
2017 149.25 84.41 102.41 84.34 101.77 46.25 117.70 82.98 52.96 75.61 
 
Cash Conversion Cycle (CCC) is a process or a cycle where the company purchases 
inventory, sells the inventory on credit as an account receivable, and then collects the account 
receivable or turns it into cash. CCC measures the time devoted in converting inventory and 
receivables to cash, as well as the amount of time the company is given to pay its bills without 
incurring any penalties.  
The cash conversion cycle is calculated as: 
CCC = DIO + DSO - DPO 
where DIO = days inventory outstanding 
DSO = days sales outstanding 
DPO = days payable outstanding 
 (3.4) 
Figure 3.1 provides a visual relationship between each components within the cash 
conversion cycle equation. The sum of DSO and DIO can be simplified as “Days for earning 
money” and DPO represents “Days for paying back the debts”. The calculated CCC can be a 
negative value which represents a good finance operation of a company. In contrast, a positive 
value indicates the days that a company should pay the suppliers in advance of receiving money 




Figure 3.1 A descriptive illustration of cash conversion cycle 
Table 3.4 shows the calculated CCC for the 10 sampled firms during 2008 - 2017.  
Table 3.4 Cash conversion cycle (CCC) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 90.46 40.61 142.09 144.34 70.11 65.53 84.94 79.30 37.20 89.93 
2009 125.68 57.76 129.04 161.48 94.09 113.89 115.25 79.66 36.36 107.92 
2010 94.13 45.09 108.42 157.48 106.05 75.83 127.75 85.28 35.05 128.15 
2011 95.12 51.60 101.72 172.59 102.12 69.10 149.51 79.13 38.25 136.44 
2012 130.43 46.77 97.38 187.08 96.75 72.91 190.22 88.03 42.46 130.63 
2013 142.75 43.35 98.81 164.93 92.29 23.29 188.11 85.80 51.31 90.20 
2014 127.18 53.32 111.52 106.52 82.50 18.66 234.21 83.15 41.38 69.99 
2015 133.55 63.03 121.19 97.17 93.99 38.47 189.18 89.36 44.75 73.06 
2016 120.73 70.16 114.34 102.11 82.52 58.29 119.15 86.73 45.69 67.53 




Inventory Turnover (IT) is a ratio showing how many times a company's inventory is sold 
and replaced over a period of time. The days in the period can then be divided by the inventory 
turnover formula to calculate the days it takes to sell the inventory on hand. It is calculated as sales 
divided by average inventory. 
The inventory turnover is calculated as: 
Inventory Turnover = 
Cost of Goods sold
(Beginning Inventory + Ending Inventory) / 2 
 (3.5) 
The cost of goods sold can be found from the income statement of each company, and the 
average inventory can be found from the balance sheets. For example, the cost of goods sold of 
Pfizer in 2017 is $11,240 million, and the beginning inventory of Pfizer in 2017 is $6,783 million, 
the ending inventory of Pfizer in 2017 is $7,578. Putting the values into the formula, then have: 
Inventory Turnover = 
11,240 
(6,783 +7,578) / 2 
  = 1.565 ≈ 1.57 
So, the inventory turnover for Pfizer in 2017 is 1.57. All data are calculated and represented in the 
following table. 
Table 3.5 shows the calculated IT for the 10 sampled firms during 2008 - 2017.  
Table 3.5 Inventory Turnover (IT) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 1.68 2.68 3.64 1.48 1.10 3.12 3.26 1.75 4.40 1.62 
2009 1.06 1.74 3.61 1.61 0.97 2.74 3.23 1.59 4.37 1.37 
2010 1.56 2.64 3.56 1.65 1.05 3.02 4.03 1.63 4.54 1.37 
2011 1.87 2.78 3.49 1.64 1.08 3.37 4.33 2.10 4.80 1.52 
2012 1.53 2.57 3.14 1.58 1.12 2.79 3.03 1.94 4.27 1.41 
2013 1.45 2.66 2.91 1.50 1.16 2.82 2.93 1.76 3.10 1.55 
2014 1.62 2.84 2.83 2.20 1.56 3.26 2.57 1.74 3.46 1.60 
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2015 1.46 2.90 2.65 2.40 1.66 3.12 2.81 1.63 3.34 1.46 
2016 1.72 2.90 2.68 2.41 1.60 2.15 3.55 1.61 3.59 1.56 
2017 1.57 2.56 3.00 3.66 1.46 2.67 4.45 1.51 4.09 1.83 
 
3.5.3 Capital Structure 
Capital structure describes how a firm finances its overall operations and growth by using 
different sources of funds. The composition of capital structure is a mixture of long-term debt, 
short-term debt, common equity and preferred equity that directly affects the risk and value of the 
associated business. The financial manager must decide how much money should be borrowed 
and the best mixture of debt and equity to obtain, and he must find the least expensive sources of 
funds for the company. In ratio analysis, the debt to equity ratio is widely considered the best 
reflection of a company's capital structure. 
3.5.4 Calculation of Capital Structure 
Debt to Equity (DTE) ratio compares a company's total liabilities to its total equity 
financing. While the optimal ratio varies from industry to industry, companies with very high DTE 
ratios are often considered to be a greater risk by investors and lending institutions. 
The debt to equity ratio is calculated as: 




Table 3.6 shows the calculated DTE for the 10 sampled firms during 2008 - 2017.  
Table 3.6 Debt to Equity (DTE) ratio for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
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2008 0.14 0.21 0.19 0.33 0.45 0.39 0.54 0.69 0.50 0.19 
2009 0.48 0.27 0.16 0.20 0.47 0.38 0.41 0.70 0.49 0.17 
2010 0.44 0.28 0.16 0.50 0.45 0.31 0.34 0.55 0.56 0.20 
2011 0.43 0.28 0.23 1.13 1.12 0.24 0.34 0.40 0.49 0.17 
2012 0.38 0.31 0.18 0.76 1.26 1.63 0.48 0.37 0.68 0.10 
2013 0.4 0.41 0.18 0.35 1.34 0.89 0.53 0.24 0.13 0.07 
2014 0.44 0.38 0.22 0.77 1.17 0.52 0.49 0.35 0.16 0.05 
2015 0.45 0.54 0.18 1.14 1.04 0.56 0.46 0.55 0.28 0.70 
2016 0.53 0.61 0.32 1.39 1.01 0.42 0.35 0.60 1.00 0.54 
2017 0.47 0.62 0.51 1.51 1.35 0.38 0.59 0.86 0.88 0.47 
 
 
3.5.5 Profitability Metrics 
Profitability metrics address questions about a company's financial performance. Some 
examples of profitability ratios are profit margin, return on assets (ROA), return on invested capital 
(ROIC), and return on equity (ROE). Profitability ratios are the most popular metrics used in 
financial analysis. 
3.5.6 Calculation of Profitability Metrics 
Return on Assets (ROA) is a financial ratio that shows the efficiency of a firm in using its 
assets to generate earnings. It is calculated as the net income divided by the total assets. The assets 
are read from the balance sheet and include cash and cash-equivalent items such as receivables, 
inventories, land, capital equipment as depreciated, and the value of intellectual property such as 
patents. 
The return on assets is calculated as: 
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Return on Assets = 
Net Income
Total Assets 
  (3.7) 
Table 3.7 shows the calculated ROA for the 10 sampled firms during 2008 - 2017.  
Table 3.7 Return on Assets (ROA) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
2008 7.16 16.34 15.61 31.29 11.81 6.67 18.83 -7.40 11.88 9.16 
2009 5.33 16.20 13.66 31.53 12.11 4.59 35.05 15.28 12.12 11.39 
2010 4.05 0.79 13.50 27.25 11.13 3.12 9.99 17.34 8.27 12.08 
2011 5.23 5.93 8.93 19.41 7.98 4.17 11.58 13.45 7.90 14.40 
2012 7.80 5.84 9.24 13.45 8.42 0.94 5.69 12.01 9.35 14.39 
2013 12.30 4.16 10.89 14.06 8.44 -4.08 6.88 13.45 4.68 16.94 
2014 5.35 11.69 12.38 42.34 7.63 -4.33 5.54 6.60 5.42 22.42 
2015 4.13 4.44 11.65 41.87 9.87 3.91 4.78 6.62 10.72 20.97 
2016 4.26 3.98 12.05 24.81 10.35 11.10 13.62 7.36 2.98 17.47 
2017 12.41 2.61 0.87 7.27 2.51 -3.56 2.99 -0.49 0.74 10.91 
 
Return on Invested Capital (ROIC) is calculated by taking the after-tax operating profit of 
the business and dividing it by invested capital. For mature companies, maximizing ROIC should 
be one of the key goals. More profit with lower capital means more money that the business can 
return to shareholders. 
The return on invested capital is calculated as: 





Table 3.8 shows the calculated ROIC for the 10 sampled firms during 2008 - 2017.  
Table 3.8 Return on Invested Capital (ROIC) for the sample of 10 firms during the last decade. 
Year PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
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2008 9.77 30.68 24.26 38.43 13.98 8.75 30.06 -11.49 17.47 10.98 
2009 8.46 25.83 21.00 40.46 15.27 6.42 53.33 26.83 17.74 13.49 
2010 7.02 1.71 19.65 34.41 13.67 5.58 14.89 29.12 12.38 14.59 
2011 8.58 9.34 13.39 24.45 9.84 7.03 17.60 22.24 12.65 17.67 
2012 12.90 8.94 14.22 17.87 11.24 2.31 10.03 20.30 14.82 17.77 
2013 19.65 6.52 16.39 18.56 10.18 -3.86 12.31 21.87 6.74 21.71 
2014 8.91 16.90 18.47 54.26 9.32 -3.99 9.43 10.43 7.64 28.60 
2015 7.11 6.74 17.55 54.52 12.69 5.62 7.83 10.48 15.01 26.40 
2016 7.63 6.21 17.86 33.19 12.44 14.13 20.91 11.95 4.54 22.28 
2017 19.69 4.23 1.69 10.68 3.53 -3.73 5.28 -0.68 1.86 14.20 
 
 
3.6 Ratio Analysis 
A series of timeplot graphs were conducted to display the changes of financial ratio within 
each sampled company during the last decade. The graphs provided a general insight of the trends 
of financial ratios in each company. Pearson correlation and multiple regression models were used 
to indicate nature and strength of relationship between dependent and independent quantitative 
variables.   
3.6.1 Timeplot 
A timeplot (sometimes called a time series graph) displays values against time. It is similar 
to x-y graph, but while an x-y graph can plot a variety of “x” variables. All graphs are generated 
and discussed in chapter 4. 
 
3.6.2 Pearson’s correlation coefficient  
In statistics, the Pearson’s correlation coefficient (r) is a measure of the linear correlation 
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between two variables X and Y. It was developed by Karl Pearson from a related idea introduced 
by Francis Galton in the 1880s. The first step in studying the relationship between two continuous 
variables is to draw a scatter plot of the variables to check for linearity. The correlation coefficient 
should not be calculated if the relationship is not linear. For correlation only purposes, it does not 
really matter on which axis the variables are plotted. However, conventionally, the independent 
(or explanatory) variable is plotted on the x-axis (horizontally) and the dependent (or response) 
variable is plotted on the y-axis (vertically). 
The Pearson correlation coefficient is one of the most commonly used formulas in 
correlation analysis. The formula is showed below: 
r =  
𝑛(∑ 𝑥𝑦) − (∑ 𝑥)(∑ 𝑦)
√[𝑛 ∑ 𝑥2 − (∑ 𝑥)2][𝑛 ∑ 𝑦2 − (∑ 𝑦)2]
 (3.9) 
3.6.3 Regression analysis  
In statistics, the general purpose of regression is to learn more about the relationship 
between several independent or predictor variables and a dependent or criterion variable. To 
determine the significant predictor variables, a single regression analysis was performed. The 
dependent variables selected were ROA and ROIC. The independent variables selected were DIO, 
CCC, and DTE.  
The form of a general multiple regression equation is below: 
𝑥 =  𝛼0 + 𝛽1𝑦1 + 𝛽2𝑦2 + 𝛽3𝑦3 + … (3.10) 
Where x = Dependent variable (ROA, ROE, ROIC) 
y = Independent variables (CCC, DTE) 
𝛼0 = constant coefficient  
𝛽 = coefficient for independent variables  
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Chapter 4 : Findings, Discussion, and Conclusions 
4.1 Empirical Result 
Data collected and calculated from Chapter 3 are used for a statistical analysis. Table 4.1 
provides the descriptive statistics of the 10 companies during the entire study period.    
Table 4.1 Descriptive statistics summary for the sample of 10 firms.  
Variables Mean Maximum Minimum 
Standard 
Deviation 
DSO 60 97 38 10.54 
DIO 178 375 77 72.35 
DPO 96 235 19 41.74 
CCC 142 333 -49 24.05 
IT 2.42 4.80 0.97 0.97 
DTE 52% 163% 5% 34% 
ROA 10.38% 42.34% -7.40% 8.55% 
ROIC 14.90% 54.52% -11.49% 11.43% 
 
Note: The numbers for DSO, DIO, DPO and CCC were rounded up for simplifying the data 
related to days.  
 
The sampled companies maintained an average DSO period of 60 days with a standard 
deviation of 10.54. Out of all observations, a maximum DSO period of 97 days is reported, which 
is considered much higher than that of the overall standards. Average stock turnover period is 178 
days during the study time with a deviation of 72.35. The average DPO for the whole samples is 
reported to be 96 days; which means that the companies are receiving lenient credit from their 
suppliers while following a stringent terms and conditions regarding granting credit to their 
customers. A positive average CCC period of 142 reflects an unexpected business model for the 
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sampled companies, in which suppliers are paid before the company receives payment from the 
customer.  At the same time, out of all observations, a maximum CCC period of 333 days is 
reported. The average IT of 2.42 represented that the inventory was replaced 2.42 times a year. 
The maximum inventory turnover is 4. 80, the minimum inventory turnover is 0.97 which implied 
a weak sales and, excess inventory compared with the samples’ average.  
 Debt to equity ratio measures a company’s debt relative to the total value of its equity. The 
sampled companies maintained an average DTE of 52%. The maximum debt to equity ratio is 
163% which implies that a company has been aggressive in financing its growth with debt. It may 
result in volatile earnings as a result of the additional interest expense.  
The profitability was observed from ROA and ROIC that most companies are generating 
positive returns during the study period. The total average value of ROA is 10.38% and ROIC is 
14.90%, out of which the standard deviation with respect to ROA is quite marginal to the extent 
of 8.55%. From the whole sample, the maximum profitability obtained in terms of ROA is 42.34% 
and that of ROIC is 54.52%. 
4.2 Historical trends with graphs and discussion 
One of the objectives of this research is to study and analyze historical trends in efficiency, 
capital structure and profitability ratios in the U.S. pharmaceutical industry. The data collected and 
ratios calculated in Chapter 3 were used to generate the scatter diagrams as shown below. 
The figure 4.1 shows the historical trends of DSO for the 10 companies. A lower DSO 
illustrates that the company takes fewer days to collect money from the customers. 7 of the 10 
companies can maintain an average DSO in 60 days. Pfizer has the highest DSO on average which 
implies the company has a high proportion of credit sales rather than cash sales. Biogen has the 
lowest DSO on average as 42 days.  
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The figure 4.2 shows the historical trends of DIO for the 10 companies. The DIO indicates 
how quickly the raw materials can be sold as products. Thus, the company should maintain a lower 
DIO or realize a decline in DIO during the 10 years. Abbott Laboratories has the lowest average 
DIO as 93 days while the average for the whole sample is 178 days. It implies that, if all companies 
producing similar drugs, then the storage time of raw materials in Abbott Laboratories is 50% 
shorter than others.    
The figure 4.3 shows the historical trends of DPO for the 10 companies. The DPO indicates 
how long it takes a company to pay debt to the supplier. A higher DPO helps the company to 
manage their liabilities easily compared with a lower DPO. Bristol-Myers Squibb has the highest 
average DPO of 152 days while the average for the whole sample is 96 days. All companies 
maintain the DPO higher than DSO. This implies the company manage their work capital well.    
The figure 4.4 shows the historical trends of CCC for the 10 companies. The CCC indicates 
how quickly a company can convert resource to revenue. A higher CCC is disadvantageous since 
the company may pay back debt to suppliers before they receive money from goods sold to 
customers. Bristol-Myers Squibb has the lowest average CCC of 18 days while the average for the 
whole sample is 142 days meaning that the company needed 142 days to convert cash into 
inventory, then into goods and services, and then through sales back into cash. All companies 
maintain a positive value of CCC and four of the 10 companies show a declining trend. Detailed 
data can be found in Appendix B.    
The figure 4.5 shows the historical trends of Inventory turnover (IT) for the 10 companies. 
The IT indicates how many times a company’s inventory is sold in a year. A higher IT is 
advantageous since the company may take sell products quicker than others. Abbott Laboratories 
has the highest average IT of 4 times in a year while the average for the whole sample is 2.42 times 
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in a year, meaning that a company’s inventory can be sold 2.42 times in a year. All companies 
maintain a positive value larger than 1.    
Figure 4.6 shows the historical trends of Debt to equity ratio (DTE) for the 10 companies. 
The DTE is another leverage ratio that compares a company's total liabilities to its total 
shareholders' equity. The real use of debt-equity is in comparing the ratio for firms in the same 
industry. If a firm’s debt-equity ratio varies significantly from its competitors or the averages for 
its industry, this should raise a red flag. Companies with a ratio that is too high can be at risk for 
financial problems or even a default if they cannot meet their debt obligations. Amgen has the 
highest average DTE of 97% while the average for the whole sample is 52%. 6 of the 10 companies 
show an increasing trend for the DTE.  
The figure 4.7 shows the historical trends of ROA for the 10 companies. The ROA 
measures how efficient a company's management is using its assets to generate earnings. The 
average ROA for the whole sample is 10.83%. Gilead Sciences maintains the highest average ROA 
as 25.33%. 4 of the 10 companies maintain an outstanding ROA above the 10.83%, which are 
Gilead Sciences, Biogen, Bristol-Myers Squibb, and Johnson & Johnson. Detailed data can be 
found in Appendix C.    
The figure 4.8 shows the historical trends of ROIC for the 10 companies. The ROIC is a 
calculation used to assess a company's efficiency at allocating the capital under its control to 
profitable investments. Gilead Sciences maintains the highest average ROA as 25.33%. The other 
top four companies which maintain an outstanding ROIC above the average are Biogen, Bristol-






   















































4.3 Results of Pearson’s correlation coefficient 
Two variables are needed for the calculation of Pearson correlation coefficient. The 
efficiency ratios and capital structure ratios are used as independent variables, and the profitability 
ratios are the dependent variable in the model. Table 4.1 shows the correlation matrix related to 
the relationship among efficiency ratios (DSO, DIO, DPO, CCC and IT) and capital structure ratio 
(DTE) vs. Profitability ratio (ROA) within each company. Data are taken from Table 3.1 – Table 
3.7.   
Table 4.1 Person’s correlation coefficient between ROA and financial ratios 
 Variable Y - ROA 
Variable 
X  PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
DSO -0.08 0.28 -0.77 -0.46 -0.07 -0.09 0.41 -0.24 0.07 -0.17 
DIO 0.02 0.52 -0.24 -0.01 0.42 0.39 -0.07 -0.23 -0.36 -0.06 
DPO 0.58 -0.30 0.62 -0.28 -0.36 0.55 -0.55 0.21 -0.75 -0.45 
CCC -0.26 0.60 -0.57 0.26 0.47 -0.29 0.64 -0.29 0.02 0.50 
IT -0.08 -0.49 0.29 -0.19 -0.36 -0.31 -0.02 0.23 0.37 -0.08 
DTE -0.17 -0.54 -0.82 -0.23 -0.78 -0.29 -0.31 -0.50 -0.35 0.18 
 
Note: The red color noted an outstanding negative correlation between two variables 
Table 4.2 shows the correlation matrix related to the relationship among efficiency ratios 
(DSO, DIO, DPO, CCC and IT) and capital structure ratio (DTE) vs. Profitability ratio (ROIC) 






Table 4.2 Person’s correlation coefficient between ROIC and financial ratios 
 Variable Y - ROIC 
Variable 
X  PFE MRK JNJ GILD AMG AGN BMY LLY ABT IDP 
DSO -0.10 0.19 -0.78 -0.49 -0.05 -0.07 0.41 -0.26 -0.15 0.06 
DIO -0.10 0.69 -0.26 -0.05 0.43 0.35 -0.04 -0.22 -0.12 -0.43 
DPO 0.64 -0.33 0.66 -0.31 -0.30 0.56 -0.55 0.18 -0.49 -0.76 
CCC -0.30 0.58 -0.60 0.22 0.47 -0.31 0.64 -0.29 0.50 -0.05 
IT -0.09 -0.46 0.31 -0.15 -0.37 -0.27 -0.05 0.23 -0.01 0.45 
DTE -0.06 -0.57 -0.82 -0.19 -0.77 -0.30 -0.27 -0.47 0.20 -0.30 
 
Note: The red color noted an outstanding negative correlation between two variables. 
Table 4.3 shows the correlation coefficient among efficiency ratios (DSO, DIO, DPO, CCC 
and IT), capital structure ratio (DTE) and Profitability ratio (ROA and ROIC) by using the average 
value of whole sampled companies during 2008 – 2017. 
Table 4.3 Person’s correlation coefficient between variables. 
 Variable Y  
Variable X  ROA ROIC DTE DSO DIO DPO CCC IT 
ROA 1.000 0.996 -0.694 -0.233 0.600 0.095 0.572 -0.514 
ROIC 0.996 1.000 -0.711 -0.161 0.662 0.150 0.626 -0.532 
DTE -0.694 -0.711 1.000 0.064 -0.595 -0.128 -0.586 0.279 
DSO -0.233 -0.161 0.064 1.000 0.438 0.758 0.276 0.016 
DIO 0.600 0.662 -0.595 0.438 1.000 0.533 0.920 -0.672 
DPO 0.095 0.150 -0.128 0.758 0.533 1.000 0.184 -0.287 
CCC 0.572 0.626 -0.586 0.276 0.920 0.184 1.000 -0.590 
IT -0.514 -0.532 0.279 0.016 -0.672 -0.287 -0.590 1.000 
 
Note: The red color noted an outstanding negative correlation between two variables, and green 
color highlighted the high positive correlation between two variables.  
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4.4 Results of regression analysis 
The Table 4.4 to Table 4.6 shows the results of single regression analysis, which examines 
the relationship between two variables based on the 10 sampled companies. The response variable 
chosen was “ROA”. Similar analysis can be performed for other profitability metrics such as ROIC 
and ROE. 
Table 4.4 Single regression analysis: ROA versus DIO. 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 1 31.19 31.185 4.49 0.067 
  DIO 1 31.19 31.185 4.49 0.067 
Error 8 55.56 6.945       
Total 9 86.75          
 
Note: 90.0% Confidence Interval for Bound, P-Value < 0.10 indicates that the predictor variable 
(DIO) has significant impact on dependent variable (ROA). 
 
Table 4.5 Single regression analysis: ROA versus CCC. 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 1 28.33 28.333 3.88 0.084 
CCC 1 28.33 28.333 3.88 0.084 
Error 8 58.41 7.302   
Total 9 86.75    
 
Note: 90.0% Confidence Interval for Bound, P-Value < 0.10 indicates that the predictor variable 
(CCC) has significant impact on dependent variable (ROA). 
 
Table 4.6 Single regression analysis: ROA versus DTE. 
Source DF Adj SS Adj MS F-Value P-Value 
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Regression 1 41.82 41.823 7.45 0.026 
DTE 1 41.82 41.823 7.45 0.026 
Error 8 44.93 5.616   
Total 9 86.75    
 
Note: 90.0% Confidence Interval for Bound, P-Value < 0.10 indicates that the predictor variable 
(DTE) has significant impact on dependent variable (ROA). 
The Table 4.7 shows the result of multiple regression analysis based on the 10 sampled 
companies.  
Table 4.7 Multiple regression analysis: ROA versus CCC, DTE. 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 3 46.4918 15.4973 2.31 0.176 
CCC 1 0.0000 0.0000 0.00 0.999 
DTE 1 15.0841 15.0841 2.25 0.184 
Error 6 40.2560 6.7093   
Total 9 86.7478    
 
 
It can be noted from Table 4.7 that the effects of different predictor variables on the ROA 
are not clear (or statistically significant) when aggregated together in a multiple regression 
analysis. Table 4.7 leads us to an interesting observation though: we can conclude that the DTE 
has much more impact as compared to CCC on the profitability of the industry, as evidenced by 
their respective F-values.  
Although, the regression analysis performed in this study focuses on the pharmaceutical 
industry as a whole, individual regression analysis models can also be developed for individual 
companies. As an example, the Table 4.8 below shows the result of multiple regression analysis 
for Johnson & Johnson.  
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Table 4.8 Multiple regression analysis for the individual company: ROA versus CCC, DTE. 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 2 111.51 55.754 10.73 0.007 
CCC 1 12.13 12.126 2.33 0.170 
DTE 1 63.45 63.449 12.21 0.010 
Error 7 36.36 5.195   
Total 9 147.87    
 
Note: 90.0% Confidence Interval for Bound, P-Value for DTE < 0.10 indicates that the predictor 
variable (DTE) has significant impact on dependent variable (ROIC). 
A multiple linear regression equation was generated below:  
ROA = 20.26 - 0.0518 CCC – 26.42 DTE 
Where, the coefficient of CCC is smaller than 0.1, and the P-Value of CCC is larger than 
0.1, so the effect of DTE is more significant than CCC on ROA. Thus, once again it is clear that 
the DTE has much more impact on the profitability of the company as compared to CCC. 
4.5 Conclusions 
Lean system plays an important role in the successful management of pharmaceutical 
industry. The main purpose for the company adopting the lean system is the reduction of cost and 
waste in the manufacturing process. There are several indicators that can be used to measure the 
performance of lean practices such as lead time, cycle time and Work in progress (WIP) inventory.  
A qualitative study on the 10 sampled companies reveals that all the companies adopted 
lean approaches within their organizations in various aspects. Some companies emphasized the 
usage of lean in cost reduction, some companies performed lean system in reduction of lead time, 
and others put efforts on reducing the storage of raw materials and work in progress inventory.    
46 
 
The single regression analysis reveals that days inventory outstanding (DIO), cash conversion 
cycle (CCC) and Debt to equity (DTE) have significant effects on profitability ratios. It implies that 
reducing days inventory outstanding and cash conversion cycle will improve the financial performance 
in pharmaceutical industry. When the companies need external money to maintain their operations and 
invest in future growth, a lower debt to equity is preferred. Finally, the multiple regressions analysis 
shows that the capital structure of the company has much more impact on its profitability as compared 









Appendix A: List of Sampled Companies. 
Abbreviation Name 
Rank in world 
in 2017 
Rank in the U.S. 
in 2017 
Rx sales in 2016 
(USD in million) 
PFE Pfizer  1 1 $45,906 
MRK Merck & Co. 4 2 $35,563 
JNJ Johnson & Johnson 6 3 $31,671 
GILD Gilead Sciences 7 4 $29,992 
AMG Amgen 10 6 $21,892 
AGN Allergan 12 7 $18,597 
BMY Bristol-Myers Squibb 14 8 $18,163 
LLY Eli Lily & Co 15 9 $17,173 
IDP Biogen  24 11 $9,818 
ABT Abbott Laboratories 35 12 $3,859 
 
Note: The rank in world and rank in the U.S. are based on the sales for prescription drug in 2016. Data from: Pharm Exec's Top 50 
Companies 2017, 2017. 
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PFE 195.20 305.09 147.53 42.94 
MRK 147.50 220.52 117.42 29.14 
JNJ 57.02 85.68 12.96 25.56 
GILD 132.24 180.89 108.68 24.05 
AMG 263.58 332.90 172.10 55.34 
AGN 125.31 172.94 73.19 31.70 
BMY 25.67 116.40 -48.72 54.13 
LLY 181.76 204.29 147.64 18.80 
CELG 172.08 238.35 55.34 63.47 
ABT 122.15 163.47 107.61 16.34 
 


















PFE 6.80 12.41 4.05 3.17 
MRK 7.20 16.34 0.79 5.55 
JNJ 10.88 15.61 0.87 4.05 
GILD 25.33 42.34 7.27 11.88 
AMG 9.03 12.11 2.51 2.80 
AGN 2.25 11.1 -4.33 5.05 
BMY 11.50 35.05 2.99 9.56 
LLY 8.42 17.34 -7.40 7.66 
CELG 15.01 22.42 9.16 4.39 
ABT 7.41 12.12 0.74 3.85 
 






















PFE 10.97 19.69 7.02 4.88 
MRK 11.71 30.68 1.71 9.65 
JNJ 16.45 24.26 1.69 6.07 
GILD 32.68 54.52 10.68 14.94 
AMG 11.22 15.27 3.53 3.32 
AGN 3.83 14.13 -3.99 6.09 
BMY 18.17 53.33 5.28 14.32 
LLY 14.11 29.12 -11.49 12.72 
CELG 18.77 28.60 10.98 5.82 
ABT 11.09 17.74 1.86 5.55 
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